Canada markets open in 8 hours 31 minutes

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.6100-0.0700 (-2.61%)
At close: 04:00PM EST
2.6100 0.00 (0.00%)
After hours: 08:00PM EST

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees199

Key Executives

NameTitlePayExercisedYear Born
Mr. Sheldon L. KoenigPresident, CEO & Director1.2MN/A1966
Mr. Benjamin O. LookerGeneral Counsel550.35kN/A1982
Dr. JoAnne Micale Foody FACC, M.D.Chief Medical Officer771.19kN/A1966
Mr. Benjamin Halladay M.B.A.Chief Financial OfficerN/AN/A1986
Mr. Glenn P. BrameChief Technical Operations OfficerN/AN/A1958
Tiffany Aldrich M.B.A.Associate Director of Corporate CommunicationsN/AN/AN/A
Ms. Betty Jean SwartzChief Business OfficerN/AN/AN/A
Mr. Eric J. Warren R.Ph.Chief Commercial OfficerN/AN/A1972
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate Governance

Esperion Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2024 is 7. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.